A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment

1. Delord, J.-P.
2. Argilés, G.
3. Fayette, J.
4. Wirth, L.
5. Kasper, S.
6. Siena, S.
7. Mesia, R.
8. Berardi, R.
9. Cervantes, A.
10. Dekervel, J.
11. Zhao, S.
12. Sun, Y.
13. Hao, H.-X.
14. Tiedt, R.
15. Vicente, S.
16. Myers, A.
17. Siu, L.L.